Trutakna Injection, Solution
NDC Package 85052-101-04

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Trutakna (atacicept) injection is tRUTAKNA is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression.This indication is approved under accelerated approval based on reduction of proteinuria. This formulation utilizes a injection, solution delivery system. Marketed by Vera Therapeutics, Inc, this product is identified by NDC 85052-101 and is authorized under FDA application BLA761486.

Identification & Billing

NDC Package Code
85052-101-04
Package Description
4 SYRINGE, GLASS in 1 CARTON / 1 INJECTION, SOLUTION in 1 SYRINGE, GLASS (85052-101-01)
Product Code
85052-101
11-Digit Billing Format
85052010104

Clinical Specifications

Proprietary Name
Trutakna
Non-Proprietary Name
Atacicept
Substance Name
Atacicept
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s)
ATACICEPT 150 mg/1
Usage Information
TRUTAKNA is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression.This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether TRUTAKNA slows kidney function decline over the long-term in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.

Regulatory & Marketing

Labeler Name
Vera Therapeutics, Inc
Product Type
Human Prescription Drug
FDA Application #
BLA761486
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
07-07-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 85052-101-04 identifies a specific commercial package of 4 syringe, glass in 1 carton / 1 injection, solution in 1 syringe, glass (85052-101-01) of Trutakna, a human prescription drug labeled by Vera Therapeutics, Inc. This injection, solution is formulated for subcutaneous use and contains atacicept as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Vera Therapeutics, Inc on July 07, 2026. The current certification is valid through December 31, 2027.

How is this Vera Therapeutics, Inc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 85052010104. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
85052-101-04
11-Digit CMS (5-4-2)
85052-0101-04

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.